FDA compliance issues at Mohali and Dadra plants
OAI status and 483 observations at Mohali and Dadra facilities could impact US generic launches and revenue.
high · analyst_question
Sunpharma Ltd — Q4 FY24
Sun Pharma reported Q4 FY24 consolidated revenue of INR 11,813 crore, up 10.1% YoY, driven by strong specialty sales (Ilumya up 21.7% to $580M globally) and India formulation gr...
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Elevated R&D and launch costs pressuring margins
Higher R&D spend (8-10% of sales) and deuruxolitinib launch costs may compress EBITDA margins in FY25.
medium · management_commentaryPricing pressure from Stelara biosimilars
Stelara biosimilar entry next year could impact Ilumya pricing and market share in the US psoriasis market.
medium · analyst_questionCurrency depreciation in emerging markets
Nigeria forex loss and broader emerging market currency volatility could impact reported revenue and profitability.
low · data_observation